Henan Newland Pharmaceutical Co. Ltd. A
Newland Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates and APIs in China. It provides pharmaceutical intermediates, including L-4-hydroxyphenylglycine methyl ester, L-hydroxyphenylglycine potassium salt, L-4-hydroxyphenylglycine, and p-Toluenesulfonic acid. The company also offers APIs, such as ropivacaine hydrochloride, naph… Read more
Henan Newland Pharmaceutical Co. Ltd. A (301277) - Total Liabilities
Latest total liabilities as of June 2025: CN¥257.50 Million CNY
Based on the latest financial reports, Henan Newland Pharmaceutical Co. Ltd. A (301277) has total liabilities worth CN¥257.50 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Henan Newland Pharmaceutical Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Henan Newland Pharmaceutical Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Henan Newland Pharmaceutical Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Henan Newland Pharmaceutical Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
EST Tools Co Ltd
SHE:300488
|
China | CN¥611.13 Million |
|
TROOPS Inc
NASDAQ:TROO
|
USA | $8.46 Million |
|
KRN Heat Exchanger and Refrigeration
NSE:KRN
|
India | ₹2.00 Billion |
|
Shanghai Shibei Hi-Tech Co Ltd B
SHG:900902
|
China | $12.41 Billion |
|
Ricardo plc
F:RIR
|
Germany | €273.90 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Henan Newland Pharmaceutical Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.29 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Henan Newland Pharmaceutical Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Henan Newland Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Henan Newland Pharmaceutical Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥270.69 Million | +69.16% |
| 2023-12-31 | CN¥160.02 Million | -8.34% |
| 2022-12-31 | CN¥174.58 Million | -33.24% |
| 2021-12-31 | CN¥261.53 Million | +25.39% |
| 2020-12-31 | CN¥208.57 Million | -- |